

Sacituzumab govitecan TROPHY-U-01

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Sacituzumab govitecan TROPHY-U-01

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: Treatment of patients with locally advanced or metastatic UC who have previously received a platinum-containing ChT and either PD-1 or PD-L1 inhibitor
 Experimental Arm: Sacituzumab govitecan
 Control Arm: Single arm



